Century Therapeutics Financials
| IPSC Stock | USD 1.30 0.09 7.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.36 | 9.9179 |
|
|
The financial analysis of Century Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Century Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Century | Select Account or Indicator |
Understanding current and past Century Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Century Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Century Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Century Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Century Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Century Therapeutics' management manipulating its earnings.
Century Therapeutics Stock Summary
Century Therapeutics competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. Century Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 170 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US15673T1007 |
| CUSIP | 15673T100 |
| Location | Pennsylvania; U.S.A |
| Business Address | 25 North 38th |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.centurytx.com |
| Phone | 267 817 5790 |
| Currency | USD - US Dollar |
Century Therapeutics Key Financial Ratios
| Return On Equity | -0.63 | ||||
| Operating Margin | (43.98) % | ||||
| Price To Sales | 38.33 X | ||||
| Revenue | 2.23 M | ||||
| Gross Profit | 5.2 M |
Century Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Century Therapeutics's current stock value. Our valuation model uses many indicators to compare Century Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Century Therapeutics competition to find correlations between indicators driving Century Therapeutics's intrinsic value. More Info.Century Therapeutics is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At present, Century Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Century Therapeutics' earnings, one of the primary drivers of an investment's value.Century Therapeutics Systematic Risk
Century Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Century Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Century Therapeutics correlated with the market. If Beta is less than 0 Century Therapeutics generally moves in the opposite direction as compared to the market. If Century Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Century Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Century Therapeutics is generally in the same direction as the market. If Beta > 1 Century Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Century Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Century Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Century Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Century Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Century Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Century Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Century Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Century Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Century Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 23.66 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 6.21 |
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |